Cultivated, Cell-Cultured & Biotechnology

TurtleTree Labs Prepares to Commercialise its First Human Cell-Based Milk Product

Bookmark
See all bookmarks
BookmarkWant to save and revisit your favorite articles? Upgrade to vegconomist+ and unlock our new bookmark feature. Subscribe today and enjoy a wide range of exclusive perks to gain a competitive edge in the vegan business world!

Singapore’s cell-based milk pioneers TurtleTree Labs has announced it is preparing to commercially launch its first product – lactoferrin – a protein usually derived from cow’s milk which the team has optimised for humans from the blueprint of human breast milk and is making it available to all.

“We have seen tremendous interest from global partners in our portfolio of human and cow’s milk products”

In addition to its protective role, lactoferrin plays an important role in brain development and inflammatory responses.

While it will be a few years before cell-based whole milk meets regulatory requirements, TurtleTree has decided to go commercial by moving deeper into the realm of milk components.

Co-founders Fengru Lin & Max Rye, TurtleTree Labs
Co-founders Fengru Lin & Max Rye, TurtleTree Labs

In December of last year, TurtleTree announced an oversubscribed $6.2 million Pre-A funding round from investors including David Yeung‘s Green Monday Ventures; Eat Beyond Global in Canada; and KBW Ventures, the venture firm of HRH Prince Khaled bin Alwaleed bin Talal Al Saud, who joined as Advisor.

Commenting on the new announcement, Max Rye, chief strategist at TurtleTree, says: “Through our frequent conversations with leading performance nutrition and infant formula companies, we have been able to identify several key ingredients. We have since seen tremendous interest from global partners in our portfolio of human and cow’s milk products. It will be an exciting year for us.”

Bookmark
See all bookmarks

Share

Newsletter

Subscribe for the vegconomist-newsletter and regularly receive the most important news from the vegan business world.

Subscribe